LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

Search

Agios Pharmaceuticals Inc

Suletud

SektorTervishoid

27.33 -0.51

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

26.44

Max

27.48

Põhinäitajad

By Trading Economics

Sissetulek

-4.6M

-108M

Müük

7.1M

20M

P/E

Sektori keskmine

3.836

66.845

Aktsiakasum

-1.85

Kasumimarginaal

-541.088

Töötajad

539

EBITDA

-18M

-120M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+43.46% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

30. apr 2026

Turustatistika

By TradingEconomics

Turukapital

140M

1.7B

Eelmine avamishind

27.84

Eelmine sulgemishind

27.33

Uudiste sentiment

By Acuity

50%

50%

154 / 351 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

Agios Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

19. nov 2025, 15:05 UTC

Tulu
Omandamised, ülevõtmised, äriostud

These Stocks Are Moving the Most Today: Nvidia, Lowe's, Target, Semrush, MP Materials, Plug Power, Dycom, and More -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Agios Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

43.46% tõus

12 kuu keskmine prognoos

Keskmine 39.71 USD  43.46%

Kõrge 65 USD

Madal 25 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Agios Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

8 ratings

6

Osta

2

Hoia

0

Müü

Tehniline skoor

By Trading Central

28.04 / 30.06Toetus ja vastupanu

Lühikene perspektiiv

Strong Bearish Evidence

Keskpikk perspektiiv

Strong Bearish Evidence

Pikk perspektiiv

Neutral Evidence

Sentiment

By Acuity

154 / 351 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Keskmine

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Agios Pharmaceuticals Inc

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat